Introduction
A growing body of evidence indicates that many human cancers are organized as cellular hierarchies initiated and maintained by a small pool of self-renewing cancer stem cells (Reya et al., 2001; Jordan et al., 2006; Dalerba et al., 2007) . Although some controversy still surrounds this model (Kelly et al., 2007; Quintana et al., 2008) , there is strong evidence for the existence of cancer stem cells in several human malignancies, including acute myeloid leukemia (AML) (Bonnet and Dick, 1997; Dick, 2008) . Within a tumor, it is only these cancer stem cells that are able to transplant the disease and differentiate into the heterogeneous cells composing the tumor. This model postulates that one reason for the relative ineffectiveness of current cancer chemotherapy regimens is that these therapies target the rapidly proliferating tumor cells, which do not include all of the cancer stem cells (Reya et al., 2001) . Thus, tumors often shrink in response to chemotherapy, but almost universally recur due to sparing of some cancer stem cells. A key implication of this cancer stem cell model is that in order to eradicate the tumor and cure the patient, therapies must target and eliminate the cancer stem cells.
Monoclonal antibodies have emerged as a potent and effective molecularly targeted therapy for human cancer, usually in combination with chemotherapy (Adams and Weiner, 2005; Finn, 2008) . Such antibodies have been demonstrated to be effective in the treatment of a number of human cancers, including rituximab for B-cell non-Hodgkin lymphoma, trastuzumab for HER2-positive breast carcinomas, cetuximab for colorectal carcinomas and head and neck squamous cell carcinomas, alemtuzumab for chronic lymphocytic leukemia (CLL) and T-cell lymphoma, and others (Adams and Weiner, 2005; Finn, 2008) . Antibodies effective against cancer are believed to function by several mechanisms including, antibody-dependent cellular cytotoxicity, stimulation of complement-dependent cytotoxicity, inhibition of signal transduction, or direct induction of apoptosis (Cheson and Leonard, 2008) . In some cases, an individual therapeutic antibody may function through several of these mechanisms simultaneously. Because of their target antigen specificity and mechanisms of action, monoclonal antibodies are able to deliver their therapeutic effects with minimal toxicity. Given the need to develop agents that can target and eliminate cancer stem cells, and the antigen specificity and efficacy of monoclonal antibodies, recent investigation has focused on the development of monoclonal antibodies targeting cancer stem cell antigens. This review will focus on the pre-clinical investigation of monoclonal antibodies targeting human AML stem cells.
Human AML stem cells
Human AML is a clonal malignancy characterized by the accumulation of immature myeloid cells defective in their maturation and function. Much is now known about the biology of AML, including chromosomal translocations resulting in gene fusions, chromosomal and subchromosomal deletions of putative tumor suppressor genes, dysregulation of programmed cell death, single-gene mutations correlating with leukemia, and derangements of the telomere/telomerase system (Gilliland et al., 2004) . A model has been proposed that AML results from the combination of mutations that fall into two broad categories: (1) stimulators of proliferation (for example, Ras, FLT3 and c-kit) and (2) inhibitors of differentiation (for example, CBF, CEBPA and MLL) (Gilliland and Griffin, 2002; Gilliland et al., 2004) . In order for AML to develop, cells must acquire at least one mutation from each category; however, in most cases of human AML, the molecular identity of such mutations is unknown.
Recent experiments have added to our fundamental knowledge by demonstrating that AML, similar to normal hematopoiesis, is composed of a hierarchy of cells that is maintained by a small pool of leukemia stem cells (LSC) (Tan et al., 2006; Dick, 2008) . Stem cells in any biological process are defined by the properties of self-renewal, which is the ability to give rise to progeny identical to the parent through cell division, and multipotency, which is the ability to give rise to all the differentiated cells of that biological process (Reya et al., 2001) . Most of the cells within AML do not possess these properties, which are restricted to the infrequent LSC that are able to maintain the leukemia. Both in vitro and in vivo experimental approaches using fluorescence-activated cell sorting-purified subpopulations of leukemia cells were utilized to identify human AML LSC. Culture of AML subpopulations on bone marrow feeder cells identified long-term culture-initiating activity in the CD34 þ CD38À leukemia fraction of most samples assayed Blair et al., 1998) . Dick and colleagues were the first to establish xenotransplantation models for human AML, and used this assay to identify long-term engrafting AML subpopulations (Lapidot et al., 1994; Bonnet and Dick, 1997) . In published reports assaying a variety of clinical and biological subtypes of AML, LSC were found to be negative for expression of lineage markers (Lin-), positive for expression of CD34, and negative for expression of CD38 (Bonnet and Dick, 1997; Blair et al., 1998; Ailles et al., 1999; Levis et al., 2005) . In normal human hematopoietic development, this Lin-CD34 þ CD38À fraction is known to be enriched for hematopoietic stem cells (HSC), leading to a proposal that AML LSC arise from mutational transformation of HSC (Bonnet and Dick, 1997) . However, human HSC have been shown to be positive for expression of CD90, whereas AML LSC have been found to lack expression of this marker (Baum et al., 1992; Craig et al., 1993; Murray et al., 1995; Blair et al., 1997; Miyamoto et al., 2000) . We have recently shown that the Lin-CD34 þ CD38ÀCD90À fraction of human cord blood contains a non-HSC multipotent progenitor, and hypothesize that this multipotent progenitor is the cell of origin for human AML (Majeti et al., 2007) , although it is possible that loss of CD90 expression occurs as a consequence of leukemic transformation of HSC. Similar to the normal hematopoietic differentiation pathway, these LSC in turn give rise to leukemia progenitor cells with the surface immunophenotype of CD34 þ CD38 þ , which further differentiate into the bulk leukemic blast population defined as CD34À.
AML affects 13,000 adults annually in the United States, most of them over the age of 65 years (Lowenberg et al., 1999; Estey and Dohner, 2006) . Current standard of care includes treatment with several cycles of high-dose chemotherapy and often includes allogeneic hematopoietic cell transplantation. Even with these aggressive treatments, which have significant side effects, 5-year overall survival is between 30-40%, and much lower for those over age of 65 years (Lowenberg et al., 1999; Estey and Dohner, 2006) . AML is a heterogeneous disorder with several different pathological classification schemes, including the FrenchAmerican-British and the more recent World Health Organization classification (Bennett et al., 1976; Vardiman et al., 2009) . The World Health Organization scheme was developed to reflect the molecular understanding of several subtypes of AML and to take into account the prognostic importance of cytogenetic abnormalities. Immunophenotyping by flow cytometry is routinely performed on clinical specimens and shows that most, but not all, human AML samples are predominantly CD34 positive (Vardiman et al., 2009) . In published reports assaying a variety of subtypes of CD34-positive AML samples, LSC have been demonstrated to reside in the Lin-CD34 þ CD38À subpopulation of cells. The clinical significance of the cancer stem cell model for AML is suggested by a study that correlated the percentage of CD34 þ CD38À LSC at the time of diagnosis with the duration of relapse free survival in 92 AML patients (van Rhenen et al., 2005) . Those patients with 43.5% AML LSC had a median relapse free survival of 5.6 months compared to those with o3.5% AML LSC who had a median relapse free survival of 16.0 months (P ¼ 0.02), suggesting the importance of LSC in the clinical outcome of human AML.
New controversies over the identification of human AML LSC The initial identification of human AML LSC was accomplished through xenotransplantation of fluorescence-activated cell sorting-purified subpopulations into immunodeficient NOD/SCID mice that lack B and T lymphocytes (Bonnet and Dick, 1997) . Although these mice exhibited bone marrow engraftment of a subset of AML samples, the levels of human chimerism were often quite low and required transplantation of thousands of cells. This prompted the development of more permissive mouse models, most recently the NOD/SCID/IL2Rg À/À (NSG) strain, which is additionally deficient in natural killer cells (Ishikawa et al., 2005 Shultz et al., 2005 Shultz et al., , 2007 . The first AML NSG xenotransplantation experiments supported the finding that LSC are exclusively contained in the CD34 þ CD38À subpopulation . In this report, as few as 1000 CD34 þ CD38À AML cells serially transplanted the disease. In contrast, CD34 þ CD38 þ or CD34À cells from either the primary human AML samples or subsequent xenografts failed to engraft, despite the transplantation of greater than 10 6 cells. However, recently the concept that all AML LSC are contained within the CD34 þ CD38À population has been challenged by the finding that many anti-CD38 antibodies, including those utilized in the original isolation of LSC, inhibit engraftment of CD34 þ CD38 þ leukemia cells through an Fc-dependent mechanism (Taussig et al., 2008) . When this mechanism was inhibited either by blockade of Fc receptors with immunoglobulin or through the use of immunosuppressive antibodies, AML repopulating activity was detected in the CD34 þ CD38 þ population. Moreover, CD34 þ CD38 þ cells engrafted in NSG mice, contrary to the results of the first report with these mice . A second report from the same group investigated the surface immunophenotype of AML LSC from patient samples with nucleophosmin mutations (NPM1c), and determined that in approximately half of the cases, LSC were exclusively contained in the CD34À fraction, whereas the other half exhibited LSC-activity in both the CD34 þ and CD34À fractions (Taussig et al., 2010) . These results indicate that the surface immunophenotype of AML LSC remains an open question for investigation, particularly with the more permissive NSG xenotransplantation assay.
Cell surface antigens preferentially expressed on AML LSC compared with HSC One strategy for the development of monoclonal antibodies targeting human AML stem cells, involves first identifying cell surface antigens preferentially expressed on AML LSC compared with normal HSC. A number of antigens expressed on AML blasts have been reported, and monoclonal antibodies targeting several of these antigens are in pre-clinical development. However, this discussion will be restricted to those antigens demonstrated to be expressed on functional LSC defined by expression on engrafting leukemia-initiating cells in xenotransplantation assays (Table 1) .
One of the first antigens reported to be preferentially expressed on human AML LSC is the high-affinity interleukin-3 (IL-3) receptor a-chain, also known as CD123 (Jordan et al., 2000) . By flow cytometry, CD123 was found to be expressed on nearly all CD34 þ CD38À cells from 18 primary AML samples, whereas no expression was detected on CD34 þ CD38À cells from five normal bone marrow specimens. Transplantation assays in NOD/SCID mice found that in three out of 
Abbreviations: HSC, hematopoietic stem cell; LSC, leukemia stem cell; NK, natural killer; SIRPa, signal regulatory protein-a.
Antibody therapy for AML LSC R Majeti three samples investigated, all mice transplanted with CD34 þ CD123 þ cells engrafted, whereas no mice transplanted with CD34 þ CD123À cells engrafted. No functional assays were conducted with normal hematopoietic cells to validate the lack of expression of CD123 on HSC. However, a separate report demonstrated that CD34 þ CD38-CD123 þ cord blood cells were capable of initiating multilineage hematopoiesis in NOD/SCID mice, suggesting that normal HSC may express CD123 (Taussig et al., 2005) . Since this first description (Jordan et al., 2000) , a number of other investigators have reported increased expression of CD123 on CD34 þ CD38À AML LSC (Testa et al., 2004; Florian et al., 2006; Yalcintepe et al., 2006) . The Dick lab reported the identification of increased expression of CD44 on engrafting CD34 þ CD38À cells from multiple AML samples compared with normal human cord blood (Jin et al., 2006) . Furthermore, they showed that the CD44-6v isoform was differentially expressed using an isoform-specific antibody. The percentage of CD34 þ CD38À cells expressing CD44 was neither reported nor were engraftment studies comparing the leukemia-initiating activity of CD44 þ and CD44À subpopulations. In this report, an activating CD44-specific antibody was demonstrated to eradicate AML LSC, but not normal cord blood or bone marrow CD34 þ CD38À engraftment (discussed in detail in the next section). This result indicates the preferential nature of CD44 expression on AML LSC. CD44 is a widely expressed protein with a number of alternatively spliced isoforms. The specific isoform(s) differentially expressed between AML LSC and normal HSC, apart from CD44-6v, have neither been reported nor has any functional difference in AML LSC been reported for these isoforms.
CLL-1, C-type lectin-like molecule-1, was identified by a Dutch group of investigators as an AML LSC-specific surface molecule (van Rhenen et al., 2007) . CLL-1 was found to be expressed on a fraction of CD34 þ CD38À AML cells, ranging from 0-100% with a median of 33% of cells, from 77 out of 89 patient samples evaluated. In the majority of the 10 normal bone marrow samples evaluated, CLL-1 was not expressed on CD34 þ CD38À cells. Notably, CLL-1 expression was also neither detected on CD34 þ CD38À cells from regenerating bone marrow post chemotherapy nor on granulocyte colonystimulating factor-mobilized peripheral blood. A total of three NOD/SCID-engrafting patient samples were identified, and in all three 100% of the CD34 þ cells were also CLL-1 positive. Hence, it was not surprising that in these three cases, isolated CD34 þ CLL-1 þ cells engrafted AML as well. Finally, examination of serial bone marrow samples from several patients determined that CLL-1 expression on CD34 þ CD38À cells tracked with clinical remission or relapse status. The same group had previously investigated CLL-1 expression in normal tissues and found no expression outside the hematopoietic system, with expression restricted to granulocytes and monocytes (Bakker et al., 2004) .
CD96 expression on AML LSC was identified using a signal sequence trap strategy to identify proteins expressed in CD34 þ CD38-AML cells that possess a signal sequence, and are, therefore, likely cell surface molecules (Hosen et al., 2007) . Analysis of CD96 expression on a panel of human AML samples and normal bone marrow demonstrated expression on the majority of LSC assayed, but only on approximately 5% of normal HSC. CD96-positive and CD96-negative cells were purified by fluorescence-activated cell sorting from five human AML samples and transplanted into newborn immunodeficient mice. In four out of five cases, only the CD96-positive cells yielded long-term leukemic engraftment, indicating that AML LSC express CD96. Initially, CD96 was identified as a T-cell surface molecule that is highly upregulated upon T-cell activation (Wang et al., 1992) . CD96 is expressed at low levels on resting T and natural killer cells and is strongly upregulated upon stimulation in both cell types (Wang et al., 1992) . It is not expressed on other hematopoietic cells, and examination of its expression pattern showed that it is only otherwise present on some intestinal epithelia (Wang et al., 1992; Gramatzki et al., 1998) .
In our own work, we identified increased expression of CD47 on primary human AML stem cells Majeti et al., 2009) . By flow cytometry, CD47 was more highly expressed on multiple specimens of primary AML compared with normal bone marrow HSC (Lin-CD34 þ CD38-CD90 þ ), which expressed low but detectable CD47. Moreover, CD47 expression did not discriminate subpopulations within a given AML sample, as the bulk AML blasts expressed similar levels of CD47 as the CD34 þ CD38-fraction. In one sample, we determined that the CD34 þ CD38-fraction contained a majority of CD47hi-expressing cells (99%) with a rare CD47lo-expressing population (1%). When this CD47lo-expressing population was isolated and functionally assayed by xenotransplantation, it engrafted normal multilineage hematopoiesis. Moreover, this particular AML sample harbored a FLT3-ITD mutation that was not present in the CD47lo-expressing population or in the engrafted cells, suggesting that the CD34 þ CD38-CD47lo population contained residual normal HSC ). This prospective separation of normal HSC from AML LSC based on differential expression of CD47 demonstrates the significance of CD47 as an AML LSC marker. Further investigation of CD47 determined that it is expressed widely at low levels in most tissues. This finding has significant implications for monoclonal antibody therapies targeting CD47 and is discussed in more detail below.
A recent bioinformatic analysis of genes differentially expressed between purified CD34 þ CD38-AML cells and normal bone marrow CD34 þ CD38À cells identified CD32 (FCGR2) and CD25 (IL2RA) as LSCspecific surface molecules (Saito et al., 2010) . Examination of 61 AML cases by flow cytometry determined that CD32 was expressed on 21 (34%) and CD25 was expressed on 15 (25%) of these samples. Further investigation of CD32 expression revealed three patterns of expression: CD32-a with a single positive peak, CD32-b with a bimodal expression showing a minor CD32-positive population and CD32-c with a single negative peak. The relative proportion of patterns CD32-a and CD32-b among the 21 CD32-positive patient samples was not reported. Upon xenotransplantation into NSG mice, CD34 þ CD38-CD32 þ cells from CD32-a patient samples engrafted with AML. On the contrary, CD34 þ CD38-CD32 þ cells did not exhibit leukemia-initiating activity from CD32-b patient samples, which was restricted to the CD34 þ CD38-CD32-cells. These data indicate that CD32 is expressed on AML LSC only from a minority of patient samples. Regarding functional investigation of CD25, the authors reported that CD34 þ CD38-CD25 þ AML cells engrafted in all four recipients evaluated, but did not mention results of engraftment studies conducted with CD34 þ CD38-CD25À cells. Notably, CD25 expression has recently been reported to be an adverse prognostic factor when expressed on greater than 10% of AML blasts, and its expression correlated with minimal residual disease (Terwijn et al., 2009 ). In the final experiments investigating CD32 and CD25, expression of these antigens on normal cells and tissues was reported (Saito et al., 2010) . Expression of both antigens was found to be restricted to cells of the hematopoietic system, although in the case of CD32, a large number of alveolar macrophages in the lung were identified with high levels of expression. Functional xenotransplantation experiments demonstrated that HSC function could be isolated in the CD34 þ CD38-CD32-or CD34 þ CD38ÀCD25À fraction of human cord blood, suggesting that elimination of CD32À or CD25-expressing cells will not target normal HSC.
Monoclonal antibodies targeting AML LSC-specific surface antigens
According to the cancer stem cell model, curative therapies must target and eliminate all cancer stem cells. Monoclonal antibodies are well positioned as cancer stem cell-targeting therapies given their antigen specificity and generally minimal toxicity. In the case of AML, the anti-CD33 monoclonal antibody conjugate gemtuzumab ozogamicin (Mylotarg) was originally given accelerated approval by the FDA for the treatment of relapsed AML in elderly patients, in whom it induced some complete remissions (Burnett and Mohite, 2006; Stasi et al., 2008) . Moreover, a new report suggests that CD33 is expressed on a subset of CD34 þ CD38À LSC that can be killed by Mylotarg in vitro (Jawad et al., 2010) . However, post-approval clinical trials demonstrated no benefit from the addition of Mylotarg to induction or maintenance therapy, no improvement in survival outcomes, and increased hepatic toxicity. For these reasons, in June 2010, Mylotarg was voluntarily removed from the US market and is now only available as an investigational agent in clinical trials.
Recently, novel antibodies targeting several of the AML LSC-specific antigens outlined above have been developed. A monoclonal antibody directed against CLL-1 has been reported to stimulate antibody-dependent cellular cytotoxicity of primary AML blasts, although efficacy against LSC was not reported (Zhao et al., 2010) . Additional antibodies targeting CD44, CD123 and CD47 have been investigated in pre-clinical models for the ability to target and eliminate primary AML LSC (Table 2) .
CD44
Monoclonal antibody targeting of AML LSC was first reported with the activating anti-CD44 antibody H90 (Jin et al., 2006) . Several different treatment models were established in NOD/SCID mice and used to assess antibody efficacy. In the first model, antibody treatment was initiated 10 days after transplantation of CD34 þ CD38À AML LSC with either control IgG or H90 administered three times per week. After 3 weeks, mice were sacrificed and analyzed for bone marrow AML engraftment, which identified a marked decrease in all four samples reported. In the second model, antibody treatment was initiated 3-6 weeks after transplantation in the setting of more established disease. Treatment starting at 3 weeks post transplantation resulted in significant elimination of leukemia in two out of two samples; however, initiation of therapy at 4-6 weeks post transplantation did not reduce bone marrow leukemic engraftment in two additional samples. In contrast, anti-CD44 antibody treatment of mice engrafted with cord blood or bone marrow CD34 þ cells had no effect on normal hematopoietic engraftment, indicating the specificity of the antibody effect for AML. To investigate targeting of the LSC-population in these models, two strategies were employed. First, the percentage and absolute number of CD34 þ CD38À cells remaining in the bone marrow after treatment were determined and found to be significantly reduced with H90 treatment compared with control for AML, but not cord blood. Second, bone marrow from control IgG or H90-treated mice was assayed for functional LSC by secondary transplantation; unlike control, no engraftment was detected in mice transplanted with cells from H90-treated mice. Collectively, these experiments demonstrate that the anti-CD44 antibody H90 is able to target and eliminate AML LSC in vivo, but that the effect is limited to situations with a lower burden of disease.
The mechanism by which H90 mediated the elimination of AML LSC was investigated. This antibody had been previously demonstrated to induce the differentiation of primary AML blasts in vitro (Charrad et al., 1999) . Investigation of its effect on AML in vivo demonstrated that leukemic blasts increased expression of markers of mature myeloid cells (CD14, CD15 or CD11b) in bone marrow from mice treated with H90, suggesting that induction of differentiation also occurs in vivo (Jin et al., 2006) . Additional experiments indicated that cells from H90-treated mice exhibited decreased short-term homing to the bone marrow and spleen in secondary recipients, and also exhibited altered LSC fates with localized but not disseminated growth. Thus, it appears the mechanism of H90 action against AML LSC is multifactorial.
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CD123
The AML LSC-specific antibody furthest along in clinical development is an antibody targeting CD123. Studies investigating the efficacy of the anti-CD123 antibody 7G3 in xenotransplantation models were recently reported (Jin et al., 2009) . As with CD44, several different assays were used to investigate targeting of CD123 in NOD/SCID models. In the first model, bulk AML or isolated CD34 þ CD38À cells were incubated ex vivo with the 7G3 antibody before transplantation into NOD/SCID mice. Such ex vivo incubation markedly reduced the engraftment of 10 out of 11 primary AML samples, but only 2 out of 5 samples of normal bone marrow or cord blood. The reduction in engraftment was sustained in five out of seven samples assessed at 8-10 weeks post transplantation. LSC targeting was suggested by the finding that, ex vivo 7G3 treatment reduced the number of CD34 þ CD38-AML cells in the bone marrow of xenotransplanted mice from three samples. A second model involved the administration of 7G3 to NOD/SCID mice 24 h post transplantation of AML cells, and resulted in statistically significant reduction in engraftment in only one out of three samples. A final established disease model initiated antibody treatment 28 days post transplantation resulting in a significant reduction in bone marrow engraftment in only two out of five mice. No inhibitory effects were observed in mice transplanted with normal bone marrow cells. Secondary transplantation studies conducted with two of these samples demonstrated reduced bulk AML and CD34 þ CD38À engraftment in the bone marrow, but not complete elimination. These data suggest that AML LSC were targeted in 7G3-treated mice, but not eradicated. Collectively, these data indicate that in NOD/SCID models 7G3 is able to inhibit engraftment of AML LSC, but has limited efficacy against established disease.
Several different mechanisms were investigated for the activity of 7G3 against AML LSC. Short-term homing and direct intrafemoral injection studies determined that 7G3 markedly inhibited AML LSC homing to the bone marrow and that this effect was only partially mediated by immune effector cells (natural killer and/or other CD122-dependent cells). The 7G3 antibody is known to inhibit the ability of IL-3 to bind and activate CD123. In vitro studies demonstrated that 7G3 inhibited spontaneous and IL-3-induced proliferation of CD34 þ CD38-AML cells. This proliferation could not be assessed in NOD/SCID mice as mouse IL-3 is not able to activate human CD123. It is possible that in human patients, 7G3 will have a more profound impact on AML LSC than in mouse models due to this additional mechanism.
A human IgG1 chimeric variant of 7G3 has been generated for clinical development. This chimeric antibody retains human CD123 binding and neutralization, Majeti et al.
Abbreviations: AML, acute myeloid leukemia; IL-3, interleukin-3; LSC, leukemia stem cell.
Antibody therapy for AML LSC R Majeti but is likely to be less immunogenic when administered to human patients. Pre-clinical toxicity studies conducted in cynomolgus monkeys yielded no antibodyrelated toxic effects, including no abnormalities of hematological parameters. This same chimeric variant has been investigated in a phase I clinical trial of relapsed or refractory high-risk AML (ClinicalTrials. gov ID: NCT00401739), and an interim update reported no treatment-related hematologic or metabolic toxicity, with two mild infusion reactions and one infection considered possibly related to the treatment (Roberts et al., 2008) . No grade 3-4 adverse events were observed in the 26 patients enrolled at the time of this report. Of the eight patients enrolled in the two highest dose cohorts, one complete response has been observed. Clearly, further clinical studies are needed to determine the efficacy of this antibody in larger numbers of AML patients.
CD47
As detailed above, we identified increased expression of CD47 on AML LSC compared with normal HSC from multiple primary specimens of AML. CD47 is a widely expressed immunoglobulin superfamily member transmembrane protein implicated in multiple cellular processes and a number of protein-protein interactions (Brown and Frazier, 2001) . In one such interaction, CD47 serves as the ligand for signal regulatory protein-a (SIRPa), which is expressed on phagocytic cells, including macrophages and dendritic cells, that when activated initiates a signal transduction cascade resulting in the inhibition of phagocytosis (Oldenborg et al., 2000 Blazar et al., 2001; Okazawa et al., 2005; Barclay and Brown, 2006) . In this way, CD47 functions as a 'do not eat me' signal by binding to SIRPa and delivering a dominant inhibitory signal. This function led us to hypothesize that increased expression of CD47 on human AML LSC contributes to pathogenesis by inhibiting phagocytosis of these cells through the interaction of CD47 with SIRPa ( Figure 1 ). Consistent with this hypothesis, we found that expression of mouse CD47 in a CD47-deficient human AML cell line inhibited phagocytosis and facilitated engraftment in immunodeficient mice . Moreover, the upregulation of CD47 in AML appears to result from co-option of a normal protective mechanism as we observed that CD47 expression on mouse HSC and progenitors increased upon mobilization from the bone marrow into the peripheral blood in which these cells pass through phagocyte-lined sinusoids in the bone marrow, liver, and spleen . On the basis of these results, we predicted that disruption of the CD47-SIRPa interaction with a monoclonal antibody directed against CD47 would preferentially enable the phagocytosis of AML LSC (Figure 2 ). Many monoclonal antibodies have been raised against human CD47, including several that block the CD47-SIRPa interaction and some that bind a different region of CD47 and do not block this interaction (Subramanian et al., 2006) . We first investigated the ability of these anti-CD47 antibodies to enable the phagocytosis of AML LSC in vitro with human and mouse macrophage effector cells . In both cases, blocking, but not nonblocking, anti-CD47 monoclonal antibodies enabled phagocytosis of human AML LSC. Moreover, no phagocytosis was detected with normal bone marrow CD34 þ cells, indicating the preferential effect for AML LSC. Using mouse macrophages, we determined that an anti-mouse SIRPa antibody also enabled phagocytosis of AML LSC, consistent with our proposed mechanism.
With these in vitro results demonstrating a potent effect of anti-CD47 antibodies against AML LSC, we conducted two different in vivo experimental models to establish CD47 targeting as a viable therapeutic strategy ). First, we utilized an ex vivo coating assay in which AML LSC were incubated with IgG1 isotype control, anti-CD45, or blocking anti-CD47 antibody. Unlike controls, cells coated with anti-CD47 antibody failed to engraft when transplanted into NSG mice. Second, we established a treatment model in which NSG mice were first transplanted with AML LSC from three independent samples, then 8-12 weeks later once express increased levels of CD47 that contribute to pathogenesis by binding phagocyte SIRPa, which delivers a potent inhibitory 'do not eat me' signal that predominates over a pro-phagocytic 'eat me' stimulus. robust bone marrow engraftment had been established, the mice were treated with either control IgG or a blocking anti-CD47 antibody. In these mice, anti-CD47 antibody treatment resulted in the rapid clearance of circulating AML in the peripheral blood. Furthermore, eight out of eight mice had marked decreases in the level of AML in the bone marrow, with three of these eight exhibiting complete clearance. Investigation of targeting of LSC showed a marked reduction of CD34 þ LSCenriched cells in the bone marrow of anti-CD47-treated mice, and more significantly, a complete absence of engraftment in secondary recipients. These results indicate that in a pre-clinical in vivo treatment model with high levels of engraftment, a blocking anti-CD47 antibody depleted AML and targeted LSC.
CD47 is widely expressed at low levels in many tissues, which could have a significant impact on its potential as a therapeutic antibody target. To explore this issue further, we utilized a rat anti-mouse CD47 antibody known to block the CD47-SIRPa interaction in several mouse experiments . First, we administered this anti-mouse CD47 antibody to wildtype mice in doses able to coat 100% of the cells in the bone marrow. There was no effect on hematopoietic stem and progenitor cells, but a severe neutropenia did develop. In addition, there was no toxicity to other organs as determined by metabolic blood parameters and histological evaluation. Second, we used anti-mouse CD47 against a mouse model of AML with high CD47 expression. In vitro, this antibody enabled phagocytosis of mouse AML cells, and in vivo, anti-CD47 treatment resulted in a survival benefit. These results suggest that regardless of its wide expression, it is possible to target CD47 on AML cells without significant toxicity.
What are the mechanisms responsible for this selective targeting? One possible explanation for this lack of significant toxicity is that in order for the anti-CD47 antibody to enable phagocytosis of a cell, that cell must express a pro-phagocytic 'eat me' signal on its surface (Figure 2) . Thus, blockade of the CD47-SIRPa interaction on cancer cells is effective because these cancer cells express an 'eat me' signal, whereas normal cells are unaffected because they lack expression of such a pro-phagocytic signal. The molecular identification of prophagocytic 'eat me' signals on AML LSC is an active area of our investigation.
Our experiments suggest that a blocking anti-CD47 antibody will not be toxic to HSC; however, one report demonstrated a role for the CD47-SIRPa interaction in the regulation of HSC engraftment. These investigators used positional genetics to characterize the molecular basis for superior human HSC engraftment in mice of the NOD background, and identified a polymorphism in NOD SIRPa that conferred enhanced binding to human CD47 (Takenaka et al., 2007) . Although this result leaves open the possibility that anti-CD47 antibody may also target HSC, it is not clear whether such targeting would occur in bone marrow stem cell niches in the nontransplantation setting. Ultimately, the best way to determine this is through non-human primate studies, and eventually human clinical trials, which we are actively pursuing.
Treatment of human AML LSC-engrafted mice with anti-CD47 antibody resulted in undetectable levels of human AML in only three out of eight mice, raising the important question of how this therapy can be optimized into a curative approach. Review of the eight leukemia-engrafted mice treated with anti-CD47 antibody suggested that those mice with starting bone marrow engraftment higher than 60% failed to completely clear human leukemia. This suggests that with higher levels of engraftment, the bone marrow may not contain sufficient phagocytic activity to completely eliminate AML. Given this consideration, there are several strategies that could potentially improve the efficacy of anti-CD47 therapy: (1) the overall level of leukemic burden could first be reduced by treatment with chemotherapy before administration of anti-CD47 antibody; (2) granulocyte colony-stimulating factor or granulocyte monocyte colony-stimulating factor could be administered to increase endogenous macrophage production and differentiation before administration of anti-CD47 antibody; (3) granulocyte colony-stimulating factor or CXCR4 antagonists could be used to mobilize the leukemia cells into the periphery and then treatment with anti-CD47 antibody would facilitate phagocytic This unmasks the pro-phagocytic stimulus on AML LSC resulting in their phagocytic elimination (right), but has no effect on normal HSC as they lack pro-phagocytic stimuli (left).
Antibody therapy for AML LSC R Majeti elimination of leukemia cells by the more numerous macrophages of the spleen and liver. We are currently investigating these approaches for optimizing anti-CD47 antibody therapy. Ultimately, it is unlikely that a single antibody will be curative for AML, as has been shown by experience with currently approved anti-cancer antibodies (Adams and Weiner, 2005; Finn, 2008) . It is more likely that curative therapies will incorporate a combination of antibodies targeting several different antigens simultaneously. In this regard, anti-CD47 antibodies offer the possibility of a novel mechanism of antibody synergy in the treatment of AML. Specifically, the combination of a blocking anti-CD47 antibody with an Fc receptor-activating anti-AML LSC antibody should synergize in stimulating the phagocytosis and elimination of AML LSC, by simultaneously blocking the 'do not eat me' signal (anti-CD47) and delivering a potent 'eat me' signal (Fc receptor-activating antibody) (Figure 3 ). In fact, we have tested this hypothesis in human non-Hodgkin lymphoma, in which we observed the synergistic eradication of established non-Hodgkin lymphoma xenografts with combination anti-CD47 and rituximab treatment (Chao et al., 2010) . We are actively working to develop a similar combination antibody therapy targeting human AML LSC.
Summary
The cancer stem cell model for AML proposes that in order to achieve cure, all LSC must be eliminated. Monoclonal antibodies targeting AML LSC-specific surface antigens represent a potentially powerful strategy to target and eliminate LSC. In recent years, a number of antigens preferentially expressed on AML LSC compared with normal HSC have been identified, including CD123, CD44, CLL-1, CD96, CD47, CD32 and CD25. Moreover, monoclonal antibodies targeting CD44, CD123 and CD47 have demonstrated efficacy against AML LSC in xenotransplantation models. Hopefully, these antibodies will ultimately prove to be effective in the treatment of human AML.
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